BC is currently classified into pathological subtypes based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HERT2), which cannot predict the response of individual patients to precision treatment regimens [28, 29]. The gene discussed is ESR1; the disease is breast cancer.